European Next Generation Sequencing Market
17
European Next Generation Sequencing Market Present to the Future! Divyaa Ravishankar, Research Analyst Healthcare
-
Upload
frost-sullivan -
Category
Business
-
view
3.494 -
download
0
Transcript of European Next Generation Sequencing Market
European Next Generation Sequencing MarketPresent to the Future!
Divyaa Ravishankar, Research Analyst
Healthcare
2
Functional Expertise
� 3 years of life sciences expertise which mainly constitutes lab research and market research.
� Working with new technologies incorporated in lab research.
� Identifying emerging technologies and tracking technological and market developments across the life sciences domain.
� Market sizing and revenue forecasting.
Industry Expertise
� Lab research experience in the areas such as:
- Diagnostic Testing by Immuno-Chromatographic Techniques.
- Genetic research in HLA typing.
� Experience base covering broad range of sectors, leveraging long-standing working relationships with leading
industry participants globally in areas like:
- Drug Discovery
- Clinical Diagnostics
- Pharmaceuticals and Biotechnology
- Donor Registries
What I bring to the Team
• Sound technical understanding of the global markets for emerging technologies in the health sciences sector.
• Ability to formulate action plans with strong communication and exceptional interpersonal skills leveraged for development of business relationships.
Career Highlights
• Currently working as a research analyst in the healthcare market research team at Frost & Sullivan.
• Two years work experience as a Senior Genetic Research Analyst at Histogenetics Pvt. Ltd, Chennai which includes
one year onsite wet lab training in Newyork, USA.
• Represented Histogenetics Ltd. at the 22nd and 23rd European Immunogenetics and Histocompatibility Conferences held at Toulouse, France (2008) and Ulm, Germany (2009).
• Represented Histogenetics Ltd. at the 35th American Society for Histocompatibility and Immunogenetics Conference at San Francisco, California, USA (2009).
• Represented Histogenetics Ltd at the National Marrow Donor Programme (NMDP) at Minneapolis, USA (2009).
• Has been part of a start up Indian stem cell donor registry DATRI Pvt. Ltd.
Education
• Master of Science (Hons.) in Biological Sciences from Birla Institute of Technology and Science, Pilani, India.
Divyaa Ravishankar
Divyaa RavishankarResearch Analyst,Life Sciences,Healthcare - Europe
Frost & SullivanChennai, India
Place photo hereShadow Background
for effect
3
Focus Points
Next Generation Sequencing – A Technology Road Map
Market Overview
Industry Challenges
Market Drivers and Restraints
Market Forecasts
Geographical Trends
End-User Analysis
Strategic Recommendations
4
A Technology Road Map
Insert chart and/or graph here
20001990 2005 2010 2011
Gel-based Systems
Single-moleculeReal-time
Sequencing
Sanger’s Sequencing
Second-generation Sequencing
MassivelyParallelSequencing
Microwell Pyrosequencing
Short-read Sequencers
Capillary Sequencing
5
Market Overview and Segmentation
European NGS MarketEuropean NGS Market
Laboratories using NGS platforms as a research tool for various findings.
Laboratories providing sequencing services commercially
Major platform provider in Europe is Illumina Inc, with Life Technologies Corporation and Roche contributing significantly. Pacific Biosciences will contribute a small share in the first quarter of 2011. The European NGS market is expected to reach revenues of$1,042.2 million in 2017, at a compound annual growth rate (CAGR) of 20.8 per cent for the period 2010-2017.
Research Centres Service Providers
6
Industry Challenges
Reduction in the Cost to Sequence Human Genomes.
Increased Breadth of Application Leading to Designing of Sequencers for
Longer Reads.
Interpretation of Complex Data from Next-generation sequencing Platforms.
Industry Challenges
7
Substitution of Microarray
Technology by NGS in a
Number of Applications
within the Research Community
Europe is a Hub for
Research Laboratories
and Academicians,
Promoting the Use of NGS
Multiplexing Capabilities in
Array Format have made
DNA Arrays a Popular Choice
for Price-sensitive Researchers
Accuracy and Standardisation
are to be Achieved if NGS has
to be Applied in Diagnostic Testing
Research Labs in
Europe are Highly
Dependant on Grants
Driv
ers
Driv
ers
Cost Advantages over
the Sanger’s sequencing
and Second-generation Sequencing Platforms
Market Drivers and Restraints
Re
stra
ints
Re
stra
ints
8
Market Forecasts
Note: All figures are rounded; the base year is 2010. Source: Frost & Sullivan
9
Geographical Trends
0
20
40
60
80
100
120
140
Den
mark
Finla
ndBel
gium
Switz
erla
ndG
erman
yN
orway
Swede
n
The N
ether
lands
Port
ugalIta
lySp
ain
Fran
ceAust
ria
Icela
nd
The U
nited K
ingd
om
Countries
Geographical Distribution of Next Generation
Sequencers in Europe
Number of units installed
Current next generation platforms in use, include the Hi Seq2000, Illumina Genome Analyzer IIx, SoliD 3 Plus, SoliD 4hq ,454 GS FLX Ti, Heliscope and Polonator.
The United Kingdom
Germany
France
Spain
The Neatherlands
Italy
Belgium
Sweden
Switzerland
Norway
Austria
Finland
Denmark
Iceland
Portugal
Illumina GA IIx and Hi Seq2000 are short-read sequencers. The firm also plans to introduce upgrades for both its HiSeq 2000 and HiSeq 1000 platforms in the spring and expects reagent costs to drop to around $5,000 per genome.
Roche 454 GS FLX titanium series account for 22.18 per cent users in Europe.
SoliD 3 Plus and SoliD 4 with its subsequent upgrade to 4hq account for 12.7 per cent of users. SoliD 5500xl and 5500 SoliD sequencers recently launched, will witness increasing adoption in many labs in 2011.
Heliscope performs single molecule sequencing.
Polonator stationed at the Max Planck Institute, Europe, works on the sequencing ligation protocol.
PacBioRS - SMRT is on the verge of its release and will contribute to market share by the first quarter of 2011.
Highest
Lowest
Incre
asin
g
Source: Frost & Sullivan
Source: Frost & Sullivan
10
End - User Analysis
11
Important Factors when Choosing Next-Generation SequencingPlatforms
Libraryconstruction
Sample volume
Breadth of application
Data accuracyLow
LowHigh
Low High
1 52 3 4
1 52 3 4
1 52 3 4
Low High
1 52 3 4
High
Cost of bioinformatics
tools
Instrument cost
Sequencing
throughput
Read length
Low
LowHigh
Low High
1 52 3 4
1 52 3 4
1 52 3 4
Low High
1 52 3 4
High
Reagent costLegal/regulatory
constraintsLow High
1 52 3 4 Low High
1 52 3 4
Note: Above are the key factors influencing the choice of NGS platforms. The factors were rated on a scale of 1 to 5 with 1 = Low importance and 5 = High importance based on the end user’s input.
12
Score Chart
A survey was conducted across 50 European labs. The participants were from companies providing sequencing services and
research institutes.
The platforms were rated on a scale of 1 to 5, with 1= Poor and 5 = Excellent, based on their performance and efficiency.
• Read length• Cost of data management / bioinformatic
tools • Ease of sample preparation• Data accuracy• Breadth of application• Throughput• Reagent cost
Rank Instrument Score
1 HiSeq 2000 3.47
2 Illumina GA IIx 3.45
3 SoliD 3 Plus 3.18
4 454 GS FLX Ti 2.7
5 SoliD 4 hq 2.44
• High Throughput Genotyping• De novo sequencing• Whole genome re-sequencing• Diagnostics• Chip sequencing• Metagenomics• Targeted re-sequencing• m RNA profiling• Epigenetics
Rank Instrument Score
1 HiSeq 2000 3.3
2 Illumina GA IIx 2.9
3 Solid 3 Plus 2.8
4 454 GS FLX Ti 2.3
5 Solid 4 hq 2.1
13
Recommendations
A multidisciplinary approach.
Clinical Results backed up by sound empirical evidence.
Addressing the needs of the research community.
Need for longer read lengths, greater coverage, increased breadth of application, data accuracy.
14
Next Steps
� Request a proposal for Growth Partnership Services or Growth Consulting Services to support you and your team to accelerate the growth of your company. ([email protected])
� Join us at our annual Growth, Innovation, and Leadership 2011: A Frost & Sullivan Global Congress on Corporate Growth (www.gil-
global.com)
� Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities(www.frost.com/news)
15
Your Feedback Is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by rating this analyst briefing and provide us with any feedback you may have.
What would you like to see from Frost & Sullivan?
16
http://twitter.com/frost_sullivan
Follow Frost & Sullivan on Facebook, LinkedIn, SlideShare, and Twitter
http://www.facebook.com/FrostandSullivan
http://www.linkedin.com/companies/4506
http://www.slideshare.net/FrostandSullivan
17
Divyaa Ravishankar
Research Analyst
Healthcare
+91-44-42044706
Katja Feick
Corporate Communications
Healthcare
0049 (0) 69 7703343
For Additional Information
Noel Anderson
European Vice President
New Business Development
+44 (0)207 343 8389
Siddharth Saha
Director of Research
Healthcare
+ 44 (0) 207 343 8374
